Gene expression profiling has already been helpful in categorizing distinct subtypes of sarcomas by profile clustering [33-35] and identifying subtype specific changes in gene expression in liposarcoma, e.g. abnormal expression of cell cycle regulators in FUS-DDIT3 carrying liposarcomas [34,36-43] and even provided potential targets for new therapeutic agents like important mediators in cell cycle regulation, e.g. MDM2 [44-48]. The gene discussed is MDM2; the disease is sarcoma.